CI
ABBV icon

Carroll Investors’s AbbVie ABBV Stock Holding History

Carroll Investors’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-3,184
Closed -$436K – 41
2022
Q3 		$436K Buy
3,184
+1,129
+55% +$162K 0.35% 28
2022
Q2 		$314K Hold
2,055
– – 0.29% 25
2022
Q1 		$332K Hold
2,055
– – 0.21% 26
2021
Q4 		$277K Buy
+2,055
New +$243K 0.16% 33

Other funds holding ABBV

AWA
Arete Wealth Advisors Chicago, Illinois $1.33B AUM 25.12% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Carroll Investors's ABBV Position: Q4 2022 in Review

Carroll Investors sold out of AbbVie (ABBV) in Q4 2022, closing a stake of 3,184 shares — an estimated $436K sold.

Carroll Investors first reported a position in ABBV in Q4 2021 and held it in 4 quarters. The position peaked at $436K in Q3 2022. 3,168 funds tracked by Wall St. Rank hold ABBV as of Q4 2022.

  • Carroll Investors reported no remaining AbbVie position as of Q4 2022 after selling out during the quarter.
  • Carroll Investors sold 3,184 AbbVie shares in Q4 2022, an estimated $436K.
  • Carroll Investors first reported a position in AbbVie in Q4 2021 and held it in 4 quarters.
  • Carroll Investors's AbbVie position peaked at $436K in Q3 2022.
  • 3,168 funds tracked by Wall St. Rank held AbbVie as of Q4 2022.

Based on Carroll Investors's 13F filing for Q4 2022, filed 14 Feb 2023.